サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1790429

米国のオフィスベースラボの市場規模、シェア、動向分析：モダリティ別、サービス別、専門医別、セグメント別予測、2025年～2033年

U.S. Office-based Labs Market Size, Share & Trends Analysis Report By Modality (Single Specialty, Multi-Specialty), By Service (Cardiac, Endovascular Intervention, Venous), By Specialist, And Segment Forecasts, 2025 - 2033

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.53円
米国のオフィスベースラボの市場規模、シェア、動向分析：モダリティ別、サービス別、専門医別、セグメント別予測、2025年～2033年
出版日: 2025年07月28日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

米国のオフィスベースラボ市場サマリー

米国のオフィスベースラボの市場規模は2024年に139億米ドルと推定され、2033年には352億1,000万米ドルの推定値に達し、2025年から2033年までのCAGRは11.16%で成長すると予測されます。米国では近年、患者がオフィスベースラボを好む傾向が強まっており、外科的介入を外来で行う傾向が強まっていることが、市場成長を促進する主な要因となっています。オフィスベースラボ（OBL）は、ヘルスケア提供システムの変革に重要な役割を果たしており、医療機器、設備、その他の製品の成長を支えています。急速に移行するヘルスケア提供シナリオは、主要市場企業を、進行中の移行から最大限の利益を得るためのビジネスモデルの変革に駆り立てています。

米国における心血管および放射線処置件数の増加は、オフィスベースラボ（OBL）市場の重要な成長要因です。2024 Heart Disease and Stroke Statistics（2024年心臓病・脳卒中統計）」の報告によると、米国人口の約半数（48.6％）が冠動脈性心疾患、心不全、脳卒中、高血圧など何らかの心血管疾患を患っています。このような疾病負担の増大は、診断およびインターベンション治療に対する需要の増加につながり、市場の成長を補完しています。

特に末梢動脈疾患は、外来でのインターベンション治療の需要を促進しています。2022年に発表された米国心臓協会の報告書によると、末梢動脈疾患（PAD）は米国の40歳以上の約850万人に影響を及ぼしています。末梢動脈疾患には血管形成術、粥腫切除術、ステント留置術などの低侵襲血管インターベンションが必要とされることが多く、外来で実施されることが増えています。

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

  • 市場スナップショット
  • 市場セグメンテーション
  • 市場セグメンテーション
  • 競合情勢

第3章 市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 補助市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
    • 市場機会分析
    • 市場課題分析
  • 規制枠組みと償還シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • ビジネス環境分析ツール
    • ポーターのファイブフォース分析
    • PESTLE分析

第4章 ：米国のオフィスベースラボ市場： モダリティ別の推定・動向分析

  • 米国のオフィスベースラボ市場の動向シェア分析：モダリティ別、2024年および2033年
  • 米国のオフィスベースラボ市場のセグメントダッシュボード：モダリティ別
  • 米国のオフィスベースラボ市場の規模と予測：モダリティ別
    • 単一専門ラボ
    • 多専門ラボ
    • ハイブリッドラボ

第5章 ：米国のオフィスベースラボ市場： サービス別の推定・動向分析

  • 米国のオフィスベースラボ市場の動向シェア分析：サービス別、2024年および2033年
  • 米国のオフィスベースラボ市場のセグメントダッシュボード：サービス別
  • 米国のオフィスベースラボ市場の規模と予測：サービス別
    • 末梢血管介入
    • 心臓
    • インターベンショナルラジオロジー
    • 静脈
    • 血管内介入
    • その他

第6章 米国のオフィスベースラボ市場：専門医別の推定・動向分析

  • 米国のオフィスベースラボ市場の動向シェア分析：専門医別、2024年および2033年
  • 米国のオフィスベースラボ市場のセグメントダッシュボード：専門医別
  • 米国のオフィスベースラボ市場の規模と予測：専門医別
    • 血管外科医
    • インターベンショナルカーディオロジー
    • インターベンショナルラジオロジー
    • その他

第7章 米国のオフィスベースラボ市場：競合情勢

  • サプライヤーの競合分類
  • サービスプロバイダーの競合分類
  • 戦略マッピング
  • 企業プロファイル
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Type of procedures performed in OBLs
  • Table 4 Catheter Placement(s): Medicare base case coding scenarios
  • Table 5 Arterial Shunting Coil Embolization (if required): Medicare base case coding scenarios
  • Table 6 Hepatic Angiogram: Medicare base case coding scenarios
  • Table 7 Volume Imaging Options: Medicare base case coding scenarios
  • Table 8 CT Acquisition (maybe billed in conjunction with CPT 76377): Medicare base case coding scenarios
  • Table 9 Mapping Options: Medicare base case coding scenarios
  • Table 10 Codes applicable between mapping and treatment: Medicare base case coding scenarios
  • Table 11 Catheter Placement (Phase II): Medicare base case coding scenarios
  • Table 12 Hepatic Angiogram (Phase II): Medicare base case coding scenarios
  • Table 13 Tumor Embolization Phase II: Medicare base case coding scenarios
  • Table 14 Microspheres Administration: Authorized User Codes (AU)
  • Table 15 Post Treatment Imaging (Provider Preference): Medicare base case coding scenarios
  • Table 16 U.S. office-based labs market revenue estimates and forecast, by Modality, 2021 - 2033 (USD billion)
  • Table 17 U.S. office-based labs market revenue estimates and forecast, by Service, 2021 - 2033 (USD billion)
  • Table 18 U.S. office-based labs market revenue estimates and forecast, by Service, 2021 - 2033 (Number of Procedures)
  • Table 19 U.S. Peripheral Vascular Intervention (PVI) in OBLs market revenue estimates and forecast, by Service, 2021 - 2033 (USD Million)
  • Table 20 U.S. Peripheral Vascular Intervention (PVI) in OBLs market revenue estimates and forecast, by Service Type, 2021 - 2033 (Number of Procedures)
  • Table 21 U.S. venous procedures in OBLs market revenue estimates and forecast, by service type, 2021 - 2033 (USD Million)
  • Table 22 U.S. venous procedures in OBLs market revenue estimates and forecast, by service type, 2021 - 2033 (Number of Procedures)
  • Table 23 U.S. interventional radiology in OBLs market revenue estimates and forecast, by service type, 2021 - 2033 (USD Million)
  • Table 24 U.S. interventional radiology in OBLs market revenue estimates and forecast, by service type, 2021 - 2033 (Number of Procedures)
  • Table 25 U.S. office-based labs market revenue estimates and forecast, by Specialist, 2021 - 2033 (USD billion)
  • Table 26 Shortage of vascular surgeons by workload analysis

List of Figures

  • Fig. 1 U.S. office-based labs segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Research methodology framework
  • Fig. 10 Secondary research framework
  • Fig. 11 Secondary research framework
  • Fig. 12 Market snapshot
  • Fig. 13 Market segmentation
  • Fig. 14 Market segmentation
  • Fig. 15 Competitive landscape
  • Fig. 16 U.S. office-based labs market dynamics
  • Fig. 17 U.S. office-based labs market: Porter's five forces analysis
  • Fig. 18 U.S. office-based labs market: PESTLE analysis
  • Fig. 19 U.S. office-based labs market: Modality movement share analysis
  • Fig. 20 U.S. office-based labs market: Modality segment dashboard
  • Fig. 21 Single specialty labs market, 2021 - 2033 (USD Billion)
  • Fig. 22 Multi-specialty labs market, 2021 - 2033 (USD Billion)
  • Fig. 23 Hybrid market, 2021 - 2033 (USD Billion)
  • Fig. 24 U.S. office-based labs market: Service movement share analysis
  • Fig. 25 U.S. office-based labs market: Service segment dashboard
  • Fig. 26 Peripheral vascular intervention market, 2021 - 2033 (USD Billion)
  • Fig. 27 Peripheral vascular intervention procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 28 Atherectomy market, 2021 - 2033 (USD Billion)
  • Fig. 29 Atherectomy procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 30 Vascular angioplasty market, 2021 - 2033 (USD Billion)
  • Fig. 31 Vascular angioplasty procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 32 Stenting market, 2021 - 2033 (USD Billion)
  • Fig. 33 Stenting procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 34 Other PVI market, 2021 - 2033 (USD Billion)
  • Fig. 35 Other PVI procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 36 Cardiac market, 2021 - 2033 (USD Billion)
  • Fig. 37 Cardiac procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 38 Interventional radiology market, 2021 - 2033 (USD Billion)
  • Fig. 39 Interventional radiology procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 40 Uterine Fibroid Embolization (UFE) market, 2021 - 2033 (USD Billion)
  • Fig. 41 Uterine Fibroid Embolization (UFE) procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 42 Prostate Artery Embolization (PAE) market, 2021 - 2033 (USD Billion)
  • Fig. 43 Prostate Artery Embolization (PAE) procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 44 Y90/Oncology market, 2021 - 2033 (USD Billion)
  • Fig. 45 Y90/Oncology procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 46 Other IR market, 2021 - 2033 (USD Billion)
  • Fig. 47 Other IR procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 48 Venous market, 2021 - 2033 (USD Million)
  • Fig. 49 Venous procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 50 RFA (Radiofrequency Ablation) and EVLT (Endovenous Laser Therapy) market, 2021 - 2033 (USD Million)
  • Fig. 51 RFA (Radiofrequency Ablation) and EVLT (Endovenous Laser Therapy) procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 52 Sclerotherapy/Glue market, 2021 - 2033 (USD Million)
  • Fig. 53 Sclerotherapy/Glue procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 54 Venous stenting market, 2021 - 2033 (USD Million)
  • Fig. 55 Venous stenting procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 56 Other deep vein market, 2021 - 2033 (USD Million)
  • Fig. 57 Other deep vein procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 58 Endovascular interventions market, 2021 - 2033 (USD Million)
  • Fig. 59 Endovascular interventions procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 60 Other services market, 2021 - 2033 (USD Million)
  • Fig. 61 Other services procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 62 U.S. office-based labs market: Specialist movement share analysis
  • Fig. 63 U.S. office-based labs market: Specialist segment dashboard
  • Fig. 64 Vascular surgeons market, 2021 - 2033 (USD Billion)
  • Fig. 65 Interventional cardiologists market, 2021 - 2033 (USD Billion)
  • Fig. 66 Interventional radiologists market, 2021 - 2033 (USD Billion)
  • Fig. 67 Other specialists market, 2021 - 2033 (USD Billion)
  • Fig. 68 Suppliers' competition categorization
  • Fig. 69 Service providers' competition categorization
  • Fig. 70 Company market position analysis: Suppliers
  • Fig. 71 Company market position analysis: Service providers
  • Fig. 72 Strategy mapping
目次
Product Code: 2-68038-900-5

U.S. Office-based Labs Market Summary

The U.S. office-based labs market size was estimated at USD 13.90 billion in 2024 and is expected to reach an estimated value of USD 35.21 billion by 2033, growing at a CAGR of 11.16% from 2025 to 2033. Growing preference for office-based labs by patients in the U.S. in recent years and the increasing trend of performing surgical interventions in outpatient settings are among key factors driving the market growth. Office-based labs (OBLs) are playing a vital role in transforming the healthcare delivery system and are supporting the growth of medical devices, equipment, and other products.The rapidly transitioning healthcare delivery scenario is driving key market players to transform their business models to achieve maximum benefit from ongoing transition.

The rising number of cardiovascular and radiological procedures in the U.S. is a significant growth driver for the office-based labs (OBLs) market. Cardiovascular disease remains the leading cause of death in the U.S. A report from the 2024 Heart Disease and Stroke Statistics indicates that nearly half of the U.S. population (48.6%) has some form of cardiovascular disease, including coronary heart disease, heart failure, stroke, and high blood pressure. This growing disease burden is translating into an increased demand for diagnostic and interventional procedures, thereby supplementing market growth.

Peripheral artery disease in particular is fueling demand for outpatient interventional care. According to the American Heart Association report published in 2022, peripheral artery disease (PAD) affected approximately 8.5 million people aged 40 and in the U.S. Peripheral artery disease often requires minimally invasive vascular interventions, such as angioplasty, atherectomy, or stenting, which are increasingly being performed in outpatient settings.

U.S. Office-based Labs Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. office-based labs market report based on service, modality, and specialist:

  • Services Outlook (Revenue, USD Million, 2021 - 2033)
  • Peripheral Vascular Intervention
    • Atherectomy
    • Vascular Angioplasty
    • Stenting
    • Other PVI
  • Endovascular Interventions
  • Cardiac
  • Interventional radiology
    • Uterine Fibroid Embolization (UFE)
    • Prostate Artery Embolization (PAE)
    • Y90/Oncology
    • Other IR
  • Venous
    • RFA (Radiofrequency Ablation) and EVLT (Endovenous Laser Therapy)
    • Sclerotherapy/Glue
    • Venous Stenting
    • Other Deep Vein
  • Others
  • Services Outlook (Number of Procedures, 2021 - 2033)
  • Peripheral Vascular Intervention
    • Atherectomy
    • Vascular Angioplasty
    • Stenting
    • Other PVI
  • Endovascular Interventions
  • Cardiac
  • Interventional radiology
    • Uterine Fibroid Embolization (UFE)
    • Prostate Artery Embolization (PAE)
    • Y90/Oncology
    • Other IR
  • Venous
    • RFA (Radiofrequency Ablation) and EVLT (Endovenous Laser Therapy)
    • Sclerotherapy/Glue
    • Venous Stenting
    • Other Deep Vein
  • Others
  • Modality Outlook (Revenue, USD Million, 2021 - 2033)
  • Single Specialty
  • Multi-Specialty
  • Hybrid
  • Specialist Outlook (Revenue, USD Million, 2021 - 2033)
  • Vascular Surgeons
  • Interventional Cardiologists
  • Interventional Radiologists
  • Others

Chapter 01 Methodology And Scope

  • 1.1 Market Segmentation & Scope
  • 1.2 Segment Definitions
    • 1.2.1 Estimates And Forecast Timeline
  • 1.3 Research Methodology
    • 1.3.1 Information Procurement
      • 1.3.1.1 Purchased Database
    • 1.3.2 Gvr's Internal Database
      • 1.3.2.1 Secondary Sources
      • 1.3.2.2 Primary Research
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Three Pillars Of Market Estimation
      • 1.6.1.1 Secondary Market Research
      • 1.6.1.2 Primary Market Intelligence
        • 1.6.1.2.1. In-Depth Interviews (Idis)
        • 1.6.1.2.2. Online Survey Program
    • 1.6.2 Market Modeling & Forecasting
      • 1.6.2.1 Procedure Volume Estimation (2021-2024)
      • 1.6.2.2 Average Cost Estimation (2021-2024)
      • 1.6.2.3 Forecasting (2025-2033)
      • 1.6.2.4 Segment Share Analysis
  • 1.7 List Of Secondary Sources
  • 1.8 List Of Abbreviations
  • 1.9 Objectives
    • 1.9.1 Objective - 1
    • 1.9.2 Objective - 2
    • 1.9.3 Objective - 3

Chapter 02 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Market Segmentation
  • 2.3 Market Segmentation
  • 2.4 Competitive Landscape

Chapter 03 Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Ancillary Market Outlook
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Analysis
      • 3.2.1.1 Increasing Volume Of Cardiovascular And Radiological Procedures
        • 3.2.1.1.1. Case Study: Peripheral Vascular Interventions For Peripheral Artery Disease (Pad) In Office-Based Labs
      • 3.2.1.2 Growing Preference For Office-Based Labs Over Hospitals
        • 3.2.1.2.1. Case Study: Trends In Peripheral Vascular Interventions And The Rise Of Office-Based Laboratories In The U.S.
        • 3.2.1.2.2. Case Study: Utilization Patterns And Outcomes Of Pad Procedures In Office-Based Labs Versus Hospitals.
      • 3.2.1.3 Advancing Technology And Rising Preference For Minimally Invasive Procedures
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 High Risk Option For Severe Cases
      • 3.2.2.2 High Capital Investment And Operational Costs
    • 3.2.3 Market Opportunity Analysis
      • 3.2.3.1 Strategic Partnerships And Physician Ownership
    • 3.2.4 Market Challenges Analysis
      • 3.2.4.1 Competitive Pressure From Ambulatory Surgical Centers (Ascs) And Hospital Outpatient Departments (Hopds)
  • 3.3 Regulatory Framework & Reimbursement Scenario
    • 3.3.1 Regulatory Framework
    • 3.3.2 Reimbursement Scenario
  • 3.4 Business Environment Analysis Tools
    • 3.4.1 Porter's Five Forces Analysis
    • 3.4.2 Pestle Analysis

Chapter 04 U.S. Office-Based Labs Market: Modality Estimates & Trend Analysis

  • 4.1 U.S. Office-Based Labs Market: Modality Movement Share Analysis, 2024 & 2033
  • 4.2 U.S. Office-Based Labs Market: Modality Segment Dashboard
  • 4.3 U.S. Office-Based Labs Market Size & Forecast And Forecasts, By Modality (Usd Billion)
    • 4.3.1 Single Specialty Labs
      • 4.3.1.1 Single Specialty Labs Market, 2021 - 2033 (Usd Billion)
    • 4.3.2 Multi-Specialty Labs
      • 4.3.2.1 Multi-Specialty Labs Market, 2021 - 2033 (Usd Billion)
    • 4.3.3 Hybrid Labs
      • 4.3.3.1 Hybrid Labs Market, 2021 - 2033 (Usd Billion)

Chapter 05 U.S. Office-Based Labs Market: Service Estimates & Trend Analysis

  • 5.1 U.S. Office-Based Labs Market: Service Movement Share Analysis, 2024 & 2033
  • 5.2 U.S. Office-Based Labs Market: Service Segment Dashboard
  • 5.3 U.S. Office-Based Labs Market Size & Forecast And Forecasts, By Service (Usd Billion)
    • 5.3.1 Peripheral Vascular Intervention
      • 5.3.1.1 Reimbursement Scenario
      • 5.3.1.2 Peripheral Vascular Intervention Market, 2021 - 2033 (Usd Billion)
      • 5.3.1.3 Peripheral Vascular Intervention Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.1.4 Atherectomy
        • 5.3.1.4.1 Atherectomy Market, 2021 - 2033 (Usd Billion)
        • 5.3.1.4.2 Atherectomy Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.1.5 Vascular Angioplasty
        • 5.3.1.5.1 Vascular Angioplasty Market, 2021 - 2033 (Usd Billion)
        • 5.3.1.5.2 Vascular Angioplasty Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.1.6 Stenting
        • 5.3.1.6.1 Stenting Market, 2021 - 2033 (Usd Billion)
        • 5.3.1.6.2 Stenting Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.1.7 Other Pvi
        • 5.3.1.7.1 Other Pvi Market, 2021 - 2033 (Usd Billion)
        • 5.3.1.7.2 Other Pvi Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
    • 5.3.2 Cardiac
      • 5.3.2.1 Reimbursement Scenario
      • 5.3.2.2 Cardiac Market, 2021 - 2033 (Usd Billion)
      • 5.3.2.3 Cardiac Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
    • 5.3.3 Interventional Radiology
      • 5.3.3.1 Reimbursement Scenario
      • 5.3.3.2 Interventional Radiology Market, 2021 - 2033 (Usd Billion)
      • 5.3.3.3 Interventional Radiology Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.3.4 Uterine Fibroid Embolization (Ufe)
        • 5.3.3.4.1 Uterine Fibroid Embolization (Ufe) Market, 2021 - 2033 (Usd Billion)
        • 5.3.3.4.2 Uterine Fibroid Embolization (Ufe) Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.3.5 Prostate Artery Embolization (Pae)
        • 5.3.3.5.1 Prostate Artery Embolization (Pae) Market, 2021 - 2033 (Usd Billion)
        • 5.3.3.5.2 Prostate Artery Embolization (Pae) Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.3.6 Y90/Oncology
        • 5.3.3.6.1 Y90/Oncology Market, 2021 - 2033 (Usd Billion)
        • 5.3.3.6.2 Y90/Oncology Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.3.7 Other Ir
        • 5.3.3.7.1 Other Ir Market, 2021 - 2033 (Usd Billion)
        • 5.3.3.7.2 Other Ir Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
    • 5.3.4 Venous
      • 5.3.4.1 Reimbursement Scenario
      • 5.3.4.2 Venous Market, 2021 - 2033 (Usd Million)
      • 5.3.4.3 Venous Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.3.4 Rfa (Radiofrequency Ablation) And Evlt (Endovenous Laser Therapy)
        • 5.3.3.4.1 Rfa (Radiofrequency Ablation) And Evlt (Endovenous Laser Therapy) Market, 2021 - 2033 (Usd Billion)
        • 5.3.3.4.2 Urfa (Radiofrequency Ablation) And Evlt (Endovenous Laser Therapy) Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.3.5 Sclerotherapy/Glue
        • 5.3.3.5.1 Sclerotherapy/Glue Market, 2021 - 2033 (Usd Billion)
        • 5.3.3.5.2 Sclerotherapy/Glue Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.3.6 Venous Stenting
        • 5.3.3.6.1 Venous Stenting Market, 2021 - 2033 (Usd Billion)
        • 5.3.3.6.2 Venous Stenting Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.3.7 Other Deep Vein
        • 5.3.3.7.1 Other Deep Vein Market, 2021 - 2033 (Usd Billion)
        • 5.3.3.7.2 Other Deep Vein Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
    • 5.3.5 Endovascular Interventions
      • 5.3.5.1 Reimbursement Scenario
      • 5.3.5.2 Endovascular Interventions Market, 2021 - 2033 (Usd Million)
      • 5.3.5.3 Endovascular Interventions Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
    • 5.3.6 Others
      • 5.3.6.1 Reimbursement Scenario
      • 5.3.6.2 Other Services Market, 2021 - 2033 (Usd Million)
      • 5.3.6.3 Other Services Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)

Chapter 06 U.S. Office-Based Labs Market: Specialist Estimates & Trend Analysis

  • 6.1 U.S. Office-Based Labs Market: Specialist Movement Share Analysis, 2024 & 2033
  • 6.2 U.S. Office-Based Labs Market: Specialist Segment Dashboard
  • 6.3 U.S. Office-Based Labs Market Size & Forecast And Forecasts, By Specialist (Usd Billion)
    • 6.3.1 Vascular Surgeons
      • 6.3.1.1 Vascular Surgeons Market, 2021 - 2033 (Usd Billion)
    • 6.3.2 Interventional Cardiologists
      • 6.3.2.1 Interventional Cardiologists Market, 2021 - 2033 (Usd Billion)
    • 6.3.3 Interventional Radiologists
      • 6.3.3.1 Interventional Radiologists Market, 2021 - 2033 (Usd Billion)
    • 6.3.4 Other Specialists
      • 6.3.4.1 Other Specialists Market, 2021 - 2033 (Usd Billion)

Chapter 07 U.S. Office-Based Labs Market: Competitive Landscape

  • 7.1 Suppliers' Competition Categorization
  • 7.2 Service Providers' Competition Categorization
    • 7.2.1 Company Market Position Analysis: Suppliers
    • 7.2.2 Company Market Position Analysis: Service Provider
  • 7.3 Strategy Mapping
    • 7.3.1 New Launch And Approval
    • 7.3.2 Acquisition
    • 7.3.3 Partnership & Collaboration
    • 7.3.4 Others
  • 7.4 Company Profiles
    • 7.3.1 Koninklijke Philips N.V.
      • 7.3.1.1 Company Overview
      • 7.3.1.2 Financial Performance
      • 7.3.1.3 Product/Service Benchmarking
      • 7.3.1.4 Strategic Initiatives
    • 7.3.2 Ge Healthcare
      • 7.3.2.1 Company Overview
      • 7.3.2.2 Financial Performance
      • 7.3.2.3 Product/Service Benchmarking
      • 7.3.2.4 Strategic Initiatives
    • 7.3.3 Siemens Healthineers Ag
      • 7.3.3.1 Company Overview
      • 7.3.3.2 Financial Performance
      • 7.3.3.3 Product/Service Benchmarking
      • 7.3.3.4 Strategic Initiatives
    • 7.3.4 Medtronic Plc
      • 7.3.4.1 Company Overview
      • 7.3.4.2 Financial Performance
      • 7.3.4.3 Product/Service Benchmarking
      • 7.3.4.4 Strategic Initiatives
    • 7.3.5 Boston Scientific Corporation
      • 7.3.5.1 Company Overview
      • 7.3.5.2 Financial Performance
      • 7.3.5.3 Product/Service Benchmarking
      • 7.3.5.4 Strategic Initiatives
    • 7.3.6 Abbott
      • 7.3.6.1 Company Overview
      • 7.3.6.2 Financial Performance
      • 7.3.6.3 Product/Service Benchmarking
      • 7.3.6.4 Strategic Initiatives
    • 7.3.7 Envision Healthcare Corporation (Kkr)
      • 7.3.7.1 Company Overview
      • 7.3.7.2 Financial Performance
      • 7.3.7.3 Product/Service Benchmarking
      • 7.3.7.4 Strategic Initiatives
    • 7.3.8 Surgical Care Affiliates (Sca)
      • 7.3.8.1 Company Overview
      • 7.3.8.2 Financial Performance
      • 7.3.8.3 Product/Service Benchmarking
      • 7.3.8.4 Strategic Initiatives
    • 7.3.9 Surgery Partners
      • 7.3.9.1 Company Overview
      • 7.3.9.2 Financial Performance
      • 7.3.9.3 Product/Service Benchmarking
      • 7.3.9.4 Strategic Initiatives
    • 7.3.10 Cardiovascular Coalition
      • 7.3.10.1 Company Overview
      • 7.3.10.2 Financial Performance
      • 7.3.10.3 Product/Service Benchmarking
      • 7.3.10.4 Strategic Initiatives
    • 7.3.11 Th Medical
      • 7.3.11.1 Company Overview
      • 7.3.11.2 Financial Performance
      • 7.3.11.3 Product/Service Benchmarking
      • 7.3.11.4 Strategic Initiatives
    • 7.3.12 Vascular Care Group
      • 7.3.12.1 Company Overview
      • 7.3.12.2 Financial Performance
      • 7.3.12.3 Product/Service Benchmarking
      • 7.3.12.4 Strategic Initiatives
    • 7.3.13 Coastal Vascular Institute
      • 7.3.13.1 Company Overview
      • 7.3.13.2 Financial Performance
      • 7.3.13.3 Product/Service Benchmarking
      • 7.3.14.4 Strategic Initiatives